Literature DB >> 9541818

Results of treatment of choroidal malignant melanoma with high-dose-rate strontium-90 brachytherapy. A retrospective study of 46 patients treated between 1983 and 1995.

L Missotten1, W Dirven, A Van der Schueren, A Leys, G De Meester, E Van Limbergen.   

Abstract

PURPOSE: We review the results of treatment of small to medium-sized choroidal malignant melanomas after high-dose-rate brachytherapy with a strontium-90 applicator.
METHODS: The applicator is positioned against the sclera using an afterloading technique. Brachytherapy is completed in a single session lasting 2-4 h with the patient under local anaesthesia. From September 1983 until March 1995, 46 eyes were treated in this way. Most tumours were 7-11 mm in diameter (range from 4.5-15 mm) with a mean height of approximately 3 mm (range from 1.5-7 mm). Follow-up ranged from 6 months to 12 years (mean 49 months).
RESULTS: Thirty of the 46 eyes had at the final evaluation a nonevolutive scar (20 of these after a single application, the others with some additional treatment). In 13 eyes the tumours were in involution but their complete destruction was not yet certain, and 3 eyes were enucleated for local recurrence. Three patients developed systemic metastases. No radiogenic complications were noticed.
CONCLUSION: Strontium-90 brachytherapy is a valuable and safe treatment technique for small to medium-sized choroidal malignant melanomas. In addition the use of a strontium-90 applicator is inexpensive thanks to this element's long half-life and the short application time.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9541818     DOI: 10.1007/s004170050059

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  2 in total

1.  Assessment of targeting accuracy of a low-energy stereotactic radiosurgery treatment for age-related macular degeneration.

Authors:  Phillip J Taddei; Erik Chell; Steven Hansen; Michael Gertner; Wayne D Newhauser
Journal:  Phys Med Biol       Date:  2010-11-12       Impact factor: 3.609

2.  18 years' experience with high dose rate strontium-90 brachytherapy of small to medium sized posterior uveal melanoma.

Authors:  R van Ginderdeuren; E van Limbergen; W Spileers
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.